HighTower Advisors’s AtriCure ATRC Stock Holding History

HighTower Advisors’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-86,791	Closed	-$1.11M	–	1552
2015 Q1	$1.11M	Hold	86,791	–	–	0.02%	764
2014 Q4	$1.08M	Hold	86,791	–	–	0.02%	763
2014 Q3	$799K	Buy	+86,791	New	+$1.38M	0.01%	853

Other funds holding ATRC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

TCM

Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HighTower Advisors's ATRC Position: Q2 2015 in Review

HighTower Advisors sold out of AtriCure (ATRC) in Q2 2015, closing a stake of 86,791 shares — an estimated $1.11M sold.

HighTower Advisors first reported a position in ATRC in Q3 2014 and held it in 3 quarters. The position peaked at $1.11M in Q1 2015. 111 funds tracked by Wall St. Rank hold ATRC as of Q2 2015.

HighTower Advisors reported no remaining AtriCure position as of Q2 2015 after selling out during the quarter.
HighTower Advisors sold 86,791 AtriCure shares in Q2 2015, an estimated $1.11M.
HighTower Advisors first reported a position in AtriCure in Q3 2014 and held it in 3 quarters.
HighTower Advisors's AtriCure position peaked at $1.11M in Q1 2015.
111 funds tracked by Wall St. Rank held AtriCure as of Q2 2015.

Based on HighTower Advisors's 13F filing for Q2 2015, filed 11 Aug 2015.